Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
about
Effect of renal function on pemetrexed-induced haematotoxicityAn epigenetic mechanism for capecitabine resistance in mesotheliomaPemetrexed in advanced non-small-cell lung cancer.Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexedIdentification of Tyr residues that enhance folate substrate binding and constrain oscillation of the proton-coupled folate transporter (PCFT-SLC46A1).Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1)Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort studyRole of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1.New avenues for second-line treatment of metastatic non-small-cell lung cancer.A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed.Pharmacokinetic evaluation of pemetrexed.Treatment of elderly patients with stage IV non-small-cell lung cancer.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature.Pemetrexed-Induced Nephrogenic Diabetes Insipidus.Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy.Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3.Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane.
P2860
Q33432955-0F14E62E-BC03-466F-AEE1-F6CC816BBF5CQ33813008-89E9C37B-489D-46FC-B867-20E4644FA3B3Q34113895-474006DB-0C36-47BA-9FAE-9E9443ECD97CQ35081379-0CDC6288-A9D4-440D-9BA6-ABF0A2E462DFQ35179998-3239CB0C-3401-4A37-B5B1-26C828876367Q35437120-625027C6-18F0-48A4-B581-79375F4355A5Q35688514-30CF52FA-6B76-4E10-BD83-3F73283226FFQ36269700-C1FEC631-C7F4-4707-8344-E070F4951237Q37264121-6A9A95B5-0E11-4DA8-9DDD-0B992F02CE52Q37357304-E419DE37-77FC-4A77-B63D-4A67505ABFAEQ37421278-AE3468D7-AD09-49E9-96DC-934A0638F686Q37579650-278F2C4B-3109-454C-B581-D506CD5002ADQ37781053-39D8E35A-B243-4021-BD7B-425302BB7134Q37877715-59AF34DA-4AFC-4E4F-94CC-27B953685E40Q37965641-A8D41493-7B65-4E19-90C9-7000CF27DB4DQ38287050-FD9F1888-7993-4A75-860B-6FC8F8A1404DQ38657082-0AC1E8ED-0D3E-4553-91FF-6F68932337C0Q41629910-7B564744-BDDF-4A97-9E56-D32F519FB1A5Q42553403-DA653755-1ED7-48D8-A80D-1ACE503AB852Q44965471-6BAA0BB3-D472-4234-8B57-608E1DBB53B7Q53052634-0B67ABD2-CA73-4123-B336-1CC930288484Q54949713-5E9862E6-78AD-4A22-A3A7-82D75CA060A2
P2860
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase I and pharmacokinetic st ...... l and impaired renal function.
@ast
Phase I and pharmacokinetic st ...... l and impaired renal function.
@en
type
label
Phase I and pharmacokinetic st ...... l and impaired renal function.
@ast
Phase I and pharmacokinetic st ...... l and impaired renal function.
@en
prefLabel
Phase I and pharmacokinetic st ...... l and impaired renal function.
@ast
Phase I and pharmacokinetic st ...... l and impaired renal function.
@en
P2093
P356
P1476
Phase I and pharmacokinetic st ...... l and impaired renal function.
@en
P2093
Ajai K Chaudhary
Alain C Mita
Alan Sandler
Amita Patnaik
Andrew Goetz
Anthony W Tolcher
Chris H Takimoto
Christopher J Sweeney
Eric K Rowinsky
Jane E Latz
P304
P356
10.1200/JCO.2004.00.9720
P407
P577
2006-01-03T00:00:00Z